Greg Rachkovsky - Equilibar

Greg Rachkovsky

Inventory Specialist

Greg Rachkovsky

As inventory specialist, Greg Rachkovsky keeps up with thousands of parts and materials so that our production team always has what they need to fulfill orders. In addition, he enjoys cross training and helping with a variety of tasks and processes. “I really enjoy learning new skillsets and feeling that I contribute in multiple ways,” he said. “At the moment, I consider hand polishing and finishing of specialty products to be my niche. Polishing metal may sound boring, but it’s focused, methodic, and you get to see the results as it happens.”

Originally from Chesterfield, Virginia, Greg enjoys driving on the Blue Ridge Parkway and stopping at overlooks to enjoy the views of the mountains surrounding Equilibar.

He has had a variety of work experience prior to coming to Equilibar and is interested in science, especially physics and biology. “I’m always curious about cause and effect and understanding how things work. I love that our regulators are used for so many purposes and research,” he said. “It’s very interesting seeing applications and knowing that our products can influence so many things. Sending an order on its way makes me curious. Who is it going to and what are they going to do with it specifically?”

His goal for the future is to keep learning and helping out however he can. “My favorite thing about coming into work is talking to my co-workers about whatever comes up. Everyone is amazing and a pleasure to work with. When you spend time, effort, and thought to make a difference and it works out in a good way, there is definitely a rewarding feeling to it.”

 

Equilibar News
PUK magazine cover with stainless steel device

Journal article focuses on oligonucleotide production using pressure control with built in dampener

Oligonucleotide drugs are made up of short sections of genetic sequences and are used to target disorders in the genetic code. The first drug of this type was used in 1998 during the AIDS epidemic.  Since then, the field has accelerated rapidly and today many oligonucleotide drugs are in clinical trials, promising improvements in treatment Read More

Read More